Activities, Bill Numbers and Titles
|
|
Client: Cigna Corporate Services, LLC
|
Total amount paid by client; lobbyist is unable to report compensation at activity level: $3,437.50
|
Senate Bill
|
3
|
An Act making appropriations for the fiscal year 2020 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements
|
Neutral
|
$0.00
|
N/A
|
Senate Bill
|
730
|
An Act to require equitable access to behavioral health services for MassHealth consumers
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
1133
|
An Act to ensure prescription drug cost transparency and affordability
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
1178
|
An Act relative to promoting transparency in the pharmaceutical industry
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
907
|
An Act relative to the continuity of care of mental health treatment
|
Neutral
|
$0.00
|
N/A
|
House Bill
|
1
|
making appropriations for the fiscal year 2020 for the maintenance of the departments, boards, commissions, institutions, and certain activities of the Commonwealth, for interest, sinking fund, and serial bond requirements, and for certain permanent improvements
|
Neutral
|
$0.00
|
N/A
|
Senate Bill
|
2235
|
An Act making appropriations for the fiscal year 2020 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements
|
Neutral
|
$0.00
|
N/A
|
Senate Bill
|
683
|
An Act establishing medicare for all in Massachusetts
|
Oppose
|
$0.00
|
N/A
|
| | |
Total amount
|
$0.00
| |
|
|
|
Meals, Travel, and Entertainment Expenses
|
No meals, travel, or entertainment expenses were filed for this disclosure reporting period. |
|
|
Additional Expenses
|
No additional expenses were filed for this disclosure reporting period. |
|
|
Campaign Contributions
|
No campaign contributions were filed for this disclosure reporting period. |
|